

# Re-discovery of Chinese medicines in the immunomodulation for Sjogren's disease

Principal Investigator: Xiang LIN

## Technology

- Mouse model of SjD
- Humanized model of SjD
- Immunological assays
- Cell transplantation
- CRISPR/Cas9 gene editing
- Multiplex imaging
- High throughput flow cytometry
- Single-cell RNA-sequencing
- Spatial transcriptomics
- Proteomics/Metabolomics

## Stage of Development

- Discovery & Platform Validation (Complete)
- Lead Identification & Patent Filing (Current)
- Pre-Clinical & IND-Enabling Studies (Current/Immediate Next)
- Clinical Development (Future)
- Commercialization Planning (Ongoing in parallel)


## Key Advantages

- Integrated, Clinically-Grounded Discovery Pipeline
- Proprietary and Translational Research Tools (owned by PI' team)
- Strong Intellectual Property Foundation
- Proven Industry Validation and Collaboration
- Multidisciplinary Expertise and Network

## Opportunities

- Addressing Unmet Clinical Needs in Autoimmune Disorders
- Synergistic Drug Combinations
- Strategic Partnerships & Licensing
- Rising Interest in "Natural" Drug Sources

- Journal cover story



- Social media reports
- TV Programme




## Intellectual Property

- WO 2022/218381A1
  - 63/649,180. US Provisional
  - 63/764,996. US Provisional
- More...



## Contact

 : [linxiang@hku.hk](mailto:linxiang@hku.hk)



**HKU Med**

LKS Faculty of Medicine  
The University of Hong Kong  
香港大學李嘉誠醫學院